Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Klaria Pharma Holding AB is a pharmaceutical company specializing in developing innovative drug delivery solutions. The company's primary focus lies in the creation and commercialization of its proprietary drug delivery platform, allowing medication to be administered through a unique, easy-to-use, self-adhering film that dissolves quickly in the oral cavity. This technology aims to enhance the efficacy and speed of active ingredient absorption, providing rapid relief for acute conditions. Klaria's solutions serve various therapeutic areas, including pain management, migraine relief, and oncology, with the potential to impact numerous sectors within the healthcare industry. By improving patient compliance and experience, Klaria Pharma contributes significantly to modern medication approaches. Headquartered in Sweden, the company plays a crucial role in the Nordic pharmaceutical market, reflecting its commitment to advancing healthcare through cutting-edge technology and innovation. As pharmaceutical development trends toward personalized and efficient treatment methods, Klaria's platform stands out as a significant advancement in drug delivery methodologies.
kr 0.07
+kr 0.00 (+0.00%)
Live · 08:37 PM · Twelve Data
The business is unprofitable at the operating level (-280.72% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 299.7% YoY with margins expanding 1111.0pp.
ROIC dropped from -57.18% to -151.10%, capital efficiency is deteriorating. Negative free cash flow of -kr 35M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 143K
▲ +299.7% YoY
Net Income (TTM)
-kr 46M
▲ +18.6% YoY
Op. Margin
-24767.13%
▲ +1111.0pp YoY
ROIC
-151.10%
▼ -93.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 36M
▼ -194.3% YoY
Op. Cash Flow (TTM)
-kr 14M
▼ -186.8% YoY
Net Debt
-kr 342K
Net Cash Position
Cash & Equiv.
kr 342K
3Y CAGR: +15.3%
Continue Research
Klaria Pharma Holding AB (KLAR.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Klaria Pharma Holding AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Klaria Pharma Holding AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -24,767.1% operating margin and a -151.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh KLAR.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.